Supersaturated Drug Delivery System of Oxyberberine Based on Cyclodextrin Nanoaggregates: Preparation, Characterization, and in vivo Application
DOI: https://doi.org/10.2147/ijn.s464994
IF: 7.033
2024-06-07
International Journal of Nanomedicine
Abstract:Ziwei Huang, 1 Shanli Zhang, 1 Zehui Qin, 1 Gaoxiang Ai, 1 Minhua Li, 1 Shiting Gong, 1 Yuhong Liu, 1 Huifang Zeng, 2 Jiannan Chen, 1 Ziren Su, 1 Zhengquan Lai 3 1 School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China; 2 The First Affiliated Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China; 3 Department of Pharmacy, Shenzhen University General Hospital/Shenzhen University Clinical Medical Academy, Shenzhen University, Shenzhen, Guangdong, People's Republic of China Correspondence: Zhengquan Lai, Department of Pharmacy, Shenzhen University General Hospital/Shenzhen University Clinical Medical Academy, Shenzhen University, Shenzhen, Guangdong, People's Republic of China, Email Ziren Su, School of pharmaceutical sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China, Email Propose: Oxyberberine (OBB), one of the main metabolites of berberine derived from intestinal and erythrocyte metabolism, exhibits appreciable anti-hyperuricemic activity. However, the low water solubility and poor plasma concentration–effect relationship of OBB hamper its development and utilization. Therefore, an OBB-hydroxypropyl-β-cyclodextrin (HP-β-CD) supersaturated drug delivery system (SDDS) was prepared and characterized in this work. Methods: OBB-HP-β-CD SDDS was prepared using the ultrasonic-solvent evaporation method and characterized. Additionally, the in vitro and in vivo release experiments were conducted to assess the release kinetics of OBB-HP-β-CD SDDS. Subsequently, the therapeutic efficacy of OBB-HP-β-CD SDDS on hyperuricemia (HUA) was investigated by means of histopathological examination and evaluation of relevant biomarkers. Results: The results of FT-IR, DSC, PXRD, NMR and molecular modeling showed that the crystallized form of OBB was transformed into an amorphous OBB-HP-β-CD complex. Dynamic light scattering indicated that this system was relatively stable and maintained by formation of nanoaggregates with an average diameter of 23 nm. The dissolution rate of OBB-HP-β-CD SDDS was about 5 times higher than that of OBB raw material. Furthermore, the AUC 0-t of OBB-HP-β-CD SDDS (10.882 μg/mL&asth) was significantly higher than that of the raw OBB counterpart (0.701 μg/mL&asth). The oral relative bioavailability of OBB-HP-β-CD SDDS was also enhanced by 16 times compared to that of the raw material. Finally, in vivo pharmacodynamic assay showed the anti-hyperuricemic potency of OBB-HP-β-CD SDDS was approximately 5– 10 times higher than that of OBB raw material. Conclusion: Based on our findings above, OBB-HP-β-CD SDDS proved to be an excellent drug delivery system for increasing the solubility, dissolution, bioavailability, and anti-hyperuricemic potency of OBB. Keywords: oxyberberine, cyclodextrin, supersaturated drug delivery systems, pharmacokinetics, hyperuricemia Graphical Berberine (BBR), the main active ingredient of herbal medicine Coptidis Rhizoma and Cortex Phellodendron chinense, is extensively utilized in China for the treatment of gastrointestinal disorders. Numerous studies have shown that BBR possesses a wide spectrum of pharmacological activities, 1–5 including anti-hyperuricemic and nephroprotective effects. 6 Our previous study has indicated that BBR may act as a prodrug to be metabolized into oxyberberine (OBB) in vivo to exert its pharmacological effects by intestine flora 7 and red blood cells. 8 OBB has superior bioactive activities to BBR in various diseases, including nonalcoholic fatty liver disease, 9 inflammatory diseases, 10 diabetes, 11,12 tumor, 13,14 and acute liver injury. 15,16 In particular, OBB has been found to exhibit excellent anti-hyperuricemic activity comparable to the first-line agent febuxostat in our previous study, 17,18 indicating that OBB may be a promising anti-hyperuricemic candidate. However, there is a huge gap between the physicochemical property of OBB and BBR. Due to its transformation from a quaternary ammonium structure into a more active lactam ring with decreased polarity, OBB shows lower water solubility than BBR, and most of current formulations suitable for BBR have not performed well with OBB in our preliminary experiments, which hampers its potential clinical application. Therefore, the present study aims to design an appropriate drug delivery system to improve the water solubility and bioavailability of -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology